China (Mainland)
Assessedsupplier
Ganciclovir CAS NO.82410-32-0
- Min.Order: 0 Metric Ton
- Payment Terms: D/A,T/T
- Product Details
Keywords
- Ganciclovir manufacture
- 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
- CAS : 82410-32-0
Quick Details
- ProName: Ganciclovir
- CasNo: 82410-32-0
- Molecular Formula: C?H??N?O?
- Appearance: White crystal powder
- Application: Ganciclovir is a nucleoside analog st...
- DeliveryTime: 10days
- PackAge: 25kgs/drum
- Port: Shanghai
- ProductionCapacity: Metric Ton/Day
- Purity: 98.0%min
- Transportation: By air or by sea
- LimitNum: 0 Metric Ton
Superiority
Ganciclovir (ganciclovir), the chemical name 9- (1, 3-dihydroxy-2-propoxymethyl) guanine, belongs to the nucleoside antiviral drugs, being a kind of guanosine derivatives. It has broad-spectrum, high-efficient inhibitory effects on herpes virus and is the first-choice drug for the treatment of cytomegalovirus infection with strong effect on hepatitis B virus and adenovirus as well. It is homologue of acyclovir (ACV) with its antiviral effect being similar as, but stronger than aciclovir, having especially strong inhibitory effects on cytomegalovirus associated with AIDS patients.
Details
|
1. Induction and maintenance treatment of CMV retinitis in immunocompromised patients (including AIDS patients). 2. Prevention of cytomegalovirus infection in patients receiving organ transplants and prophylaxis of cytomegalovirus disease in HIV-positive patients with cytomegalovirus seroprevalence. For immunodeficient patients with life-threatening or vision-related cytomegalovirus (CMV) infections, such as AIDS, exogenous immunosuppressive patients associated with organ transplantation and tumor chemotherapy. Antiviral drugs, for the treatment of cytomegalovirus (CMV) infections caused by low immune capability. For antiviral drugs intermediates |
|
1. Induction and maintenance treatment of CMV retinitis in immunocompromised patients (including AIDS patients). 2. Prevention of cytomegalovirus infection in patients receiving organ transplants and prophylaxis of cytomegalovirus disease in HIV-positive patients with cytomegalovirus seroprevalence. For immunodeficient patients with life-threatening or vision-related cytomegalovirus (CMV) infections, such as AIDS, exogenous immunosuppressive patients associated with organ transplantation and tumor chemotherapy. Antiviral drugs, for the treatment of cytomegalovirus (CMV) infections caused by low immune capability. For antiviral drugs intermediates |